CN102680676A - 髓过氧化物酶(myeloperoxidase MPO)测定试剂盒(胶乳增强免疫比浊法) - Google Patents
髓过氧化物酶(myeloperoxidase MPO)测定试剂盒(胶乳增强免疫比浊法) Download PDFInfo
- Publication number
- CN102680676A CN102680676A CN2011102153900A CN201110215390A CN102680676A CN 102680676 A CN102680676 A CN 102680676A CN 2011102153900 A CN2011102153900 A CN 2011102153900A CN 201110215390 A CN201110215390 A CN 201110215390A CN 102680676 A CN102680676 A CN 102680676A
- Authority
- CN
- China
- Prior art keywords
- mpo
- antibody
- reagent
- solution
- myeloperoxidase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004816 latex Substances 0.000 title claims abstract description 25
- 229920000126 latex Polymers 0.000 title claims abstract description 25
- 102000003896 Myeloperoxidases Human genes 0.000 title abstract description 17
- 108090000235 Myeloperoxidases Proteins 0.000 title abstract description 17
- 238000003018 immunoassay Methods 0.000 title abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 34
- 210000002966 serum Anatomy 0.000 claims abstract description 20
- 239000003381 stabilizer Substances 0.000 claims abstract description 9
- 239000000243 solution Substances 0.000 claims description 24
- 238000013016 damping Methods 0.000 claims description 19
- 239000012530 fluid Substances 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 238000004879 turbidimetry Methods 0.000 claims description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 5
- 230000002421 anti-septic effect Effects 0.000 claims description 5
- 235000013905 glycine and its sodium salt Nutrition 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- CCMKPCBRNXKTKV-UHFFFAOYSA-N 1-hydroxy-5-sulfanylidenepyrrolidin-2-one Chemical compound ON1C(=O)CCC1=S CCMKPCBRNXKTKV-UHFFFAOYSA-N 0.000 claims description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000001718 carbodiimides Chemical class 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims 2
- 244000309466 calf Species 0.000 claims 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 2
- 239000012482 calibration solution Substances 0.000 claims 1
- 230000021523 carboxylation Effects 0.000 claims 1
- 238000006473 carboxylation reaction Methods 0.000 claims 1
- 238000000247 postprecipitation Methods 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 238000010790 dilution Methods 0.000 abstract description 7
- 239000012895 dilution Substances 0.000 abstract description 7
- 239000007853 buffer solution Substances 0.000 abstract description 5
- 102000004169 proteins and genes Human genes 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 abstract description 5
- 238000011088 calibration curve Methods 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000003755 preservative agent Substances 0.000 abstract 3
- 230000002335 preservative effect Effects 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000008213 purified water Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 101001099460 Homo sapiens Myeloperoxidase Proteins 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 102000051251 human MPO Human genes 0.000 abstract 1
- 229910017053 inorganic salt Inorganic materials 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000004005 microsphere Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 38
- 238000000034 method Methods 0.000 description 21
- 239000000427 antigen Substances 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 238000001514 detection method Methods 0.000 description 16
- 210000004408 hybridoma Anatomy 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 8
- 206010003445 Ascites Diseases 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 201000011244 Acrocallosal syndrome Diseases 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 208000019905 acrocephalosyndactyly Diseases 0.000 description 6
- 206010051895 acute chest syndrome Diseases 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010010803 Gelatin Chemical group 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 229920000159 gelatin Chemical group 0.000 description 3
- 239000008273 gelatin Chemical group 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical group FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013411 master cell bank Methods 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical group [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Substances [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
样品浓度 | 0.81ng/ml | 16ng/ml |
测定均值 | 0.76ng/ml | 16.7ng/ml |
标准差 | 0.0253 | 0.4031 |
批内精密度 | 7.2% | 3.8% |
样品浓度 | 0.81ng/ml | 16ng/ml |
测定均值 | 0.77ng/ml | 15.9ng/ml |
标准差 | 0.0324 | 0.4398 |
批间精密度 | 9.1% | 5.8% |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110215390.0A CN102680676B (zh) | 2011-07-29 | 2011-07-29 | 髓过氧化物酶(myeloperoxidase MPO)测定试剂盒(胶乳增强免疫比浊法) |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110215390.0A CN102680676B (zh) | 2011-07-29 | 2011-07-29 | 髓过氧化物酶(myeloperoxidase MPO)测定试剂盒(胶乳增强免疫比浊法) |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102680676A true CN102680676A (zh) | 2012-09-19 |
CN102680676B CN102680676B (zh) | 2015-06-10 |
Family
ID=46812920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110215390.0A Active CN102680676B (zh) | 2011-07-29 | 2011-07-29 | 髓过氧化物酶(myeloperoxidase MPO)测定试剂盒(胶乳增强免疫比浊法) |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102680676B (zh) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103033624A (zh) * | 2012-12-16 | 2013-04-10 | 天津市协和医药科技集团有限公司 | 一种人髓过氧化物酶化学发光免疫检测试剂盒 |
CN103308698A (zh) * | 2013-06-17 | 2013-09-18 | 北京北检·新创源生物技术有限公司 | 一种将含氨基的分子共价偶联至微球上的偶联方法 |
CN103323596A (zh) * | 2012-10-31 | 2013-09-25 | 武汉生之源生物科技有限公司 | 髓过氧化物酶含量检测试剂盒及其制备方法 |
CN104122395A (zh) * | 2013-04-28 | 2014-10-29 | 北京协和洛克生物技术有限责任公司 | 一种检测样本中髓过氧化物酶浓度的试剂盒及其制备方法 |
CN104237522A (zh) * | 2012-12-03 | 2014-12-24 | 武汉生之源生物科技有限公司 | 脂联素含量检测试剂盒及其制备方法 |
CN105223356A (zh) * | 2015-10-20 | 2016-01-06 | 常州英赞美科生物科技有限公司 | Gpi胶乳增强免疫比浊法体外定量测定诊断试剂盒 |
CN106053365A (zh) * | 2016-05-26 | 2016-10-26 | 安徽伊普诺康生物技术股份有限公司 | 一种测定髓过氧化物酶的试剂盒及其制备方法 |
CN106093387A (zh) * | 2016-05-27 | 2016-11-09 | 安徽伊普诺康生物技术股份有限公司 | 一种测定骨源性碱性磷酸酶的试剂盒 |
CN106896227A (zh) * | 2017-04-05 | 2017-06-27 | 济南蓄琪生物技术有限公司 | 一种髓过氧化物酶检测试剂盒 |
CN108387732A (zh) * | 2017-11-27 | 2018-08-10 | 南京天纵易康生物科技股份有限公司 | 一种基于双分子荧光互补技术的mpo检测试剂盒、制备及使用方法 |
CN109884322A (zh) * | 2019-03-26 | 2019-06-14 | 苏州博源医疗科技有限公司 | 一种髓过氧化物酶检测试剂及其制备和使用方法 |
CN113358869A (zh) * | 2021-06-04 | 2021-09-07 | 山东博科生物产业有限公司 | 一种稳定、灵敏的髓过氧化物酶检测试剂盒 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005075986A2 (en) * | 2004-02-06 | 2005-08-18 | Universite De Liege | Method and kit for the measurement of neutrophil cell activation |
WO2008034750A1 (en) * | 2006-09-18 | 2008-03-27 | F. Hoffmann La-Roche Ag | Natriuretic peptides for diagnosing cardiac complications due to coronary catheterization |
WO2009013053A1 (en) * | 2007-07-20 | 2009-01-29 | Universite De Liege | Combined method and kit for the sequential measurement of (1) the enzymatically active fraction and (2) the total amount of an enzyme |
CN101377492A (zh) * | 2007-08-29 | 2009-03-04 | 北京九强生物技术有限公司 | 胱抑素c测定试剂盒 |
JP2009109301A (ja) * | 2007-10-29 | 2009-05-21 | Masaharu Yoshida | Mpo−anca親和性検出方法 |
CN201654036U (zh) * | 2009-12-21 | 2010-11-24 | 东北农业大学 | Mpo奶牛隐性乳房炎检测试剂盒 |
WO2011022628A1 (en) * | 2009-08-20 | 2011-02-24 | The Board Of Regents Of The University Of Texas System | Methods and compositions for diagnosis of acute myocardial infarction (ami) |
-
2011
- 2011-07-29 CN CN201110215390.0A patent/CN102680676B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005075986A2 (en) * | 2004-02-06 | 2005-08-18 | Universite De Liege | Method and kit for the measurement of neutrophil cell activation |
WO2008034750A1 (en) * | 2006-09-18 | 2008-03-27 | F. Hoffmann La-Roche Ag | Natriuretic peptides for diagnosing cardiac complications due to coronary catheterization |
WO2009013053A1 (en) * | 2007-07-20 | 2009-01-29 | Universite De Liege | Combined method and kit for the sequential measurement of (1) the enzymatically active fraction and (2) the total amount of an enzyme |
CN101377492A (zh) * | 2007-08-29 | 2009-03-04 | 北京九强生物技术有限公司 | 胱抑素c测定试剂盒 |
JP2009109301A (ja) * | 2007-10-29 | 2009-05-21 | Masaharu Yoshida | Mpo−anca親和性検出方法 |
WO2011022628A1 (en) * | 2009-08-20 | 2011-02-24 | The Board Of Regents Of The University Of Texas System | Methods and compositions for diagnosis of acute myocardial infarction (ami) |
CN201654036U (zh) * | 2009-12-21 | 2010-11-24 | 东北农业大学 | Mpo奶牛隐性乳房炎检测试剂盒 |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103323596A (zh) * | 2012-10-31 | 2013-09-25 | 武汉生之源生物科技有限公司 | 髓过氧化物酶含量检测试剂盒及其制备方法 |
CN103323596B (zh) * | 2012-10-31 | 2015-06-03 | 武汉生之源生物科技有限公司 | 髓过氧化物酶含量检测试剂盒及其制备方法 |
CN104237522B (zh) * | 2012-12-03 | 2016-12-21 | 武汉生之源生物科技股份有限公司 | 脂联素含量检测试剂盒及其制备方法 |
CN104237522A (zh) * | 2012-12-03 | 2014-12-24 | 武汉生之源生物科技有限公司 | 脂联素含量检测试剂盒及其制备方法 |
CN103033624A (zh) * | 2012-12-16 | 2013-04-10 | 天津市协和医药科技集团有限公司 | 一种人髓过氧化物酶化学发光免疫检测试剂盒 |
CN104122395A (zh) * | 2013-04-28 | 2014-10-29 | 北京协和洛克生物技术有限责任公司 | 一种检测样本中髓过氧化物酶浓度的试剂盒及其制备方法 |
CN103308698A (zh) * | 2013-06-17 | 2013-09-18 | 北京北检·新创源生物技术有限公司 | 一种将含氨基的分子共价偶联至微球上的偶联方法 |
CN103308698B (zh) * | 2013-06-17 | 2015-04-29 | 北京北检·新创源生物技术有限公司 | 一种将含氨基的分子共价偶联至微球上的偶联方法 |
CN105223356A (zh) * | 2015-10-20 | 2016-01-06 | 常州英赞美科生物科技有限公司 | Gpi胶乳增强免疫比浊法体外定量测定诊断试剂盒 |
CN106053365A (zh) * | 2016-05-26 | 2016-10-26 | 安徽伊普诺康生物技术股份有限公司 | 一种测定髓过氧化物酶的试剂盒及其制备方法 |
CN106093387A (zh) * | 2016-05-27 | 2016-11-09 | 安徽伊普诺康生物技术股份有限公司 | 一种测定骨源性碱性磷酸酶的试剂盒 |
CN106896227A (zh) * | 2017-04-05 | 2017-06-27 | 济南蓄琪生物技术有限公司 | 一种髓过氧化物酶检测试剂盒 |
CN108387732A (zh) * | 2017-11-27 | 2018-08-10 | 南京天纵易康生物科技股份有限公司 | 一种基于双分子荧光互补技术的mpo检测试剂盒、制备及使用方法 |
CN109884322A (zh) * | 2019-03-26 | 2019-06-14 | 苏州博源医疗科技有限公司 | 一种髓过氧化物酶检测试剂及其制备和使用方法 |
CN109884322B (zh) * | 2019-03-26 | 2022-02-11 | 苏州博源医疗科技有限公司 | 一种髓过氧化物酶检测试剂及其制备和使用方法 |
CN113358869A (zh) * | 2021-06-04 | 2021-09-07 | 山东博科生物产业有限公司 | 一种稳定、灵敏的髓过氧化物酶检测试剂盒 |
CN113358869B (zh) * | 2021-06-04 | 2022-10-14 | 山东博科生物产业有限公司 | 一种稳定、灵敏的髓过氧化物酶检测试剂盒 |
WO2022252241A1 (zh) * | 2021-06-04 | 2022-12-08 | 山东博科生物产业有限公司 | 一种稳定、灵敏的髓过氧化物酶检测试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
CN102680676B (zh) | 2015-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102680676B (zh) | 髓过氧化物酶(myeloperoxidase MPO)测定试剂盒(胶乳增强免疫比浊法) | |
US4536479A (en) | Use of anti-idiotype antibodies in immunoassays | |
US4606855A (en) | Monoclonal antibody to digoxin | |
CN101988924B (zh) | 检测血液抗环瓜氨酸多肽抗体的试纸条及制备方法 | |
CN100567324C (zh) | 一种微囊藻毒素单克隆抗体及其制备方法与应用 | |
AU620872B2 (en) | Visual discrimination qualitative enzyme assay | |
US6362008B1 (en) | Generic signalling mechanism for detection of analytes | |
CN109085333A (zh) | 一种类风湿因子抗原的制备、检测试剂盒及制备方法 | |
CN102246039A (zh) | 胰岛素测定法 | |
KR102154628B1 (ko) | 반정량 수평류 면역진단 기술을 이용한 랄스토니아 솔라나세아룸과 푸사리움 옥시스포룸의 동시 진단 방법 | |
CN101477123B (zh) | 检测二乙氧基硫代磷酸酯类有机磷农药的酶联免疫试剂盒 | |
CN104020289B (zh) | 一种筛选抗原不同结合位点的单克隆抗体的方法 | |
CN104849251A (zh) | 一种快速检测地沟油的时间分辨荧光免疫方法及试剂盒 | |
CN102095855A (zh) | 杀虫晶体蛋白Cry1Ac酶联免疫吸附检测试剂盒 | |
CN104693248A (zh) | 肺炎支原体的甘油糖脂抗原 | |
CN103288872A (zh) | 甲基对硫磷半抗原及其制备方法和应用 | |
AU2011330997A1 (en) | Device and method for immunotrials | |
CN102103142B (zh) | Tafi含量的体外检测方法 | |
CN102183635A (zh) | Tafi含量的体外检测试剂盒 | |
CN109752531A (zh) | 一种检测鸡蛋中氟虫腈的试剂盒及其检测方法 | |
JP2020525763A (ja) | 脂肪性肝炎の検出に用いられる標的マーカーgp73及び検出方法 | |
Fujita et al. | An enzyme-linked immunosorbent assay for detection of linear alkylbenzene sulfonate: development and field studies | |
CN101093225A (zh) | 一种微囊藻毒素酶联免疫检测试剂盒 | |
JP4458622B2 (ja) | 免疫学的測定方法及び測定用試薬 | |
CN108459000A (zh) | 一种检测氟吡菌酰胺的时间分辨荧光试纸条及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: NANJING NORMAN BIOLOGICAL TECHNOLOGY Co.,Ltd. Document name: Notification of Patent Invention Entering into Substantive Examination Stage |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 210029 5th floor, software building, no.66-1, Majiadian Industrial Park, Tiexinqiao street, Yuhuatai District, Nanjing City, Jiangsu Province Patentee after: Nanjing Norman Biotechnology Co.,Ltd. Country or region after: China Address before: 210029 5th floor, software building, no.66-1, Majiadian Industrial Park, Tiexinqiao street, Yuhuatai District, Nanjing City, Jiangsu Province Patentee before: NANJING NORMAN BIOLOGICAL TECHNOLOGY Co.,Ltd. Country or region before: China |
|
CP03 | Change of name, title or address |
Address after: No. 197 Yaogu Avenue, Jiangbei New District, Nanjing City, Jiangsu Province, 210029 Patentee after: Nanjing Norman Biotechnology Co.,Ltd. Country or region after: China Address before: 210029 5th floor, software building, no.66-1, Majiadian Industrial Park, Tiexinqiao street, Yuhuatai District, Nanjing City, Jiangsu Province Patentee before: Nanjing Norman Biotechnology Co.,Ltd. Country or region before: China |